Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs as the Company Embarks on a Pivotal Trial for its Investigational, Allogeneic CD7-Targeted CAR-T Cell Therapy
November 12, 2024 07:05 ET
|
Wugen
Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs
Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients with Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia or T Cell Lymphoblastic Lymphoma
November 12, 2024 07:00 ET
|
Wugen
Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007
Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress
June 14, 2024 07:30 ET
|
Wugen
Wugen Presents Data at European Hematology Association (EHA) 2024 Hybrid Congress
Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June
May 20, 2024 07:03 ET
|
Wugen
Wugen Announces RMAT and PRIME Designations for WU-CART-007 and Plans to Present Positive Phase 2 Study Findings at EHA 2024
Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer
January 03, 2024 08:00 ET
|
Wugen
Wugen Strengthens Executive Leadership Team with the Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting
December 11, 2023 15:00 ET
|
Wugen
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at ASH 2023
Wugen to Present New Clinical Data for WU-CART-007 and Preclinical Data for WU-NK-101, Two Investigational Allogeneic Cell Therapies for Challenging Hematologic Cancers, at American Society of Hematology Annual Meeting & Exposition
November 02, 2023 09:43 ET
|
Wugen
-- Oral Presentation Highlights Latest Clinical Findings from First Global, In-Human Phase 1/2 Dose-Escalation Study of Anti-CD7 Off-the-Shelf Allogeneic CAR-T Cell Therapy, WU-CART-007, in...